Tolerogenic cells in allogeneic haematopoietic transplantation
Research type
Research Study
Full title
An investigation into tolerogenic cells and graft versus host disease in allogeneic haematopoietic stem cell transplantation.
IRAS ID
226012
Contact name
D.A. Pawson
Contact email
Sponsor organisation
Sheffield Hallam University
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Graft versus host disease (GvHD) is a complication of allogeneic haematopoietic transplantation which can result in patient morbidity and mortality. This research aims to investigate associations between the quantities of three tolerogenic cell types present in mobilised peripheral blood stem cell (PBSC) allografts and post-transplant recipient peripheral blood, with GvHD and other transplant outcomes. It would be advantageous to clinicians to have indicators that may predict transplant outcomes.
The three tolerogenic cell types of interest are: plasmacytoid dendritic cells (pDC), dendritic cell - 10 cells (DC-10) and type 1 regulatory T cells (Tr1 cells). All have all been linked to transplantation tolerance and are present in peripheral blood.
There may be an association between the number of pDC, DC-10 and/or Tr1 an allogeneic recipient receives in their PBSC graft, and/or between how quickly these tolerogenic cells emerge and/or their quantity, and GvHD and/or other transplant outcomes.
The study will run for 18 months and hopes to analyse 35 allografts at Leeds Teaching Hospital Trust. All adult haematopoietic allogeneic stem cell transplant patients at this hospital will be eligible for the study. Participants will be required to provide informed consent.
Samples are routinely taken from allogeneic donations for CD34 analysis. These samples will also be used to enumerate the tolerogenic cells as discussed above. The donors will not be required to donate any extra blood for the study.
The duration of the study for patients will be approximately 6 months. Samples are routinely taken from patients following transplantation at the following time points: 2, 4, 8 weeks, 3 and 6 months. In the study these samples will also be used to enumerate the tolerogenic cells discussed above. The patients will not be required to donate any extra blood for the study.
REC name
Wales REC 7
REC reference
17/WA/0288
Date of REC Opinion
13 Sep 2017
REC opinion
Favourable Opinion